Our team at Novel Therapeutics had the opportunity to visit the TMC³ High Throughput Screening & Drug Discovery Program at Texas A&M University’s Institute of Biosciences & Technology. Touring both the automated screening lab and their combinatorial chemistry laboratories giving us a front-row look at some of the most advanced platforms in translational research.
We’re working to merge AI-driven molecular design with automated screening and synthesis, focused on building and testing novel compounds derived from phytochemicals. These integrated capabilities allow us to rapidly identify hits, optimize leads, and validate function, all with precision and speed.
Grateful for the collaboration and alignment in vision. This is where computation meets chemistry, and where real therapeutic impact begins.